Platinum Chemotherapy DNA Damage in Children Study
Analysis based on 8 articles · First reported Sep 10, 2026 · Last updated Sep 11, 2026
This study may influence pharmaceutical companies developing chemotherapy drugs and supportive care treatments, potentially leading to new protective therapies and increased R&D investment in reducing chemotherapy side effects. However, the immediate market impact is limited as the findings do not change current treatment protocols and chemotherapy remains essential.
A study published in Science on 10 September 2026 reveals that platinum-based chemotherapy, while life-saving for childhood cancer, causes extensive DNA damage in healthy cells, including a previously unknown pattern of damage in the liver. Researchers from the University of Gothenburg, Wellcome Sanger Institute, University of Cambridge, Francis Crick Institute, and King s College London used the NanoSeq sequencing technique to analyze 186 samples from nine children treated with platinum-based chemotherapy, plus additional samples from children with other cancers or no treatment. The study found that children's healthy cells accumulate DNA damage equivalent to decades of aging in middle-aged adults, with some mutations being cancer drivers. The liver-specific damage appears to arise during drug breakdown in the liver and may contribute to future liver disease. The findings provide a biological explanation for why childhood cancer survivors face increased risks of secondary cancers and premature aging conditions. The research was funded by Wellcome Trust, Cancer Research UK, UK Medical Research Council, United States — National Institutes of Health, Canada — Canadian Institutes of Health Research, and others. The authors emphasize that chemotherapy remains essential and the goal is to develop protective treatments to reduce long-term side effects.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard